Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $139.32 is 202.41% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 140.03||$ 176.50|
|Low:||$ 137.19||$ 46.07|
ETFs with SRPT as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|2.6%||Principal Healthcare Innovators Index ETF (BTEC)||+2.09 (6.63%)|
|1.48%||Principal Sustainable Momentum Index ETF (PMOM)||N/A (N/A)|
|1.28%||iShares Morningstar Small-Cap Growth ETF (JKK)||-1.64 (-0.84%)|
|0.48%||John Hancock Multifactor Small Cap ETF (JHSC)||-0.72 (-2.69%)|
|0.34%||SPDR Portfolio Small Cap ETF (SPSM)||-1.19 (-3.74%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches for the treatment of rare neuromuscular diseases. Applying our proprietary, highly-differentiated and innovative RNA-targeted platform technologies, we are able to develop candidate therapies for a broad range of diseases and disorders. Our first commercial product in the U.S., EXONDYS 51, was granted accelerated approval by the FDA on September 19, 2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. A summary description of our product and main product candidates is as follows: * EXONDYS 51, our first product, uses our PMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. ... More ...
Nasdaq Official Price
Oct. 19, 2018